ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Asciminib, a first‐in‐class STAMP inhibitor targeting the ABL myristoyl pocket, has demonstrated a novel, allosteric mechanism of action distinct from ATP‐competitive TKIs, offering new opportunities for achieving deep and sustained molecular responses in CML.